| Literature DB >> 35338335 |
Sara N Stoner1, Joshua J Baty1, Jessica A Scoffield2.
Abstract
Pseudomonas aeruginosa dominates the complex polymicrobial cystic fibrosis (CF) airway and is a leading cause of death in persons with CF. Oral streptococcal colonization has been associated with stable CF lung function. However, no studies have demonstrated how Streptococcus salivarius, the most abundant streptococcal species found in individuals with stable CF lung disease, potentially improves lung function or becomes incorporated into the CF airway biofilm. By utilizing a two-species biofilm model to probe interactions between S. salivarius and P. aeruginosa, we discovered that the P. aeruginosa exopolysaccharide Psl promoted S. salivarius biofilm formation. Further, we identified a S. salivarius maltose-binding protein (MalE) that is required for promotion of biofilm formation both in vitro and in a Drosophila melanogaster co-infection model. Finally, we demonstrate that promotion of dual biofilm formation with S. salivarius is common among environmental and clinical P. aeruginosa isolates. Overall, our data supports a model in which S. salivarius uses a sugar-binding protein to interact with P. aeruginosa exopolysaccharide, which may be a strategy by which S. salivarius establishes itself within the CF airway microbial community.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35338335 PMCID: PMC9213427 DOI: 10.1038/s41396-022-01221-y
Source DB: PubMed Journal: ISME J ISSN: 1751-7362 Impact factor: 11.217
Fig. 1S. salivarius and P. aeruginosa produce an enhanced biofilm in a dual species model.
S. salivarius (Ss) was co-cultured with either of two P. aeruginosa strains (PAO1 and FRD1) in TSBYE medium in a 96-well plate for 16 h at 37 °C (n = 3 biological replicates, 6 technical). Biofilm biomass was then measured using crystal violet staining. One-way ANOVA with Šίdák’s multiple comparisons test. Error bars indicate standard deviation. ***p < 0.001, ****p < 0.0001.
Fig. 2Non-mucoid P. aeruginosa strain PAO1 promotes S. salivarius biofilm formation.
A Quantification of Ss and PAO1 biofilm CFUs was performed in a 6-h, 6-well mono- and dual-species biofilm model. Samples were cultured in TSBYE medium and B synthetic CF sputum (SCFM2), serially diluted and plated on THB agar. Data represent three biological replicates performed in triplicate. Student’s t test. Error bars indicate mean ± SD. C Confocal microscopy was performed on Ss and PAO1-GFP single and dual species biofilms in both TSBYE and SCFM2. Ss was stained with hexidium iodide. **p < 0.01, ***p < 0.001.
Fig. 3P. aeruginosa exopolysaccharide Psl promotes S. salivarius biofilm formation.
Ss was co-cultured with P. aeruginosa PAO1 strains (A) PAO1∆pslA and PAO1 pslA in TSBYE medium with 1% sucrose in a 96-well plate for 16 h at 37 °C with 5% CO2 (n = 3 biological replicates, 3 technical). Biofilm biomass was then measured using crystal violet staining. One-way ANOVA with Dunnett’s multiple comparisons test. B Quantification of Ss biofilm-forming cells after co-culturing with PAO1, PAO1∆pslA, and PAO1 pslA in TSBYE (left) and SCFM2 [50] in a 6-h, 6-well model at 37 °C with 5% CO2 (n = 3 biological replicates, each with 3 technical replicates). One-way ANOVA with Šίdák’s multiple comparisons test. C 0.5 mg/mL purified Psl was added to Ss single cultures in TSBYE with 1% sucrose in a 96-well 16-h biofilm. Crystal violet staining was used to quantify biofilm biomass. D qPCR quantification of P. aeruginosa pslA expression compared to 16S rRNA control. Student’s t test. Fluorescence microscopy images at 60× magnification of 16-h single (E) and dual species (F) biofilms of Ss and PAO1, PAO1∆pslA, and PAO1pslA+ cultured in TSBYE supplemented with 1% sucrose. Ss was stained with hexidium iodide, and Psl was stained with a FITC-conjugated α-Psl monoclonal antibody. Scale bar: 20 μm. *p < 0.05, **p < 0.01, ****p < 0.0001.
Fig. 4S. salivarius maltose-binding protein MalE promotes dual biofilm formation.
A Ss and PAO1 were cultured individually and dually in TSBYE medium at 37 °C while shaking until OD600 = 1.8 was reached. Cells were resuspended in Tris-Buffered Saline (TBS) and lysed using the Bead Blaster 24 (Benchmark). Supernatant was run on SDS page gel, and overproduced bands in the dual sample were sent to the UAB Mass Spectrometry core for identification. B Ss and PAO1 were cultured in TSBYE with 1% sucrose in a 96-well 16-h biofilm model in the presence of 0 µg/mL, 5 µg/mL or 10 µg/mL α-MalE mAbs. Biofilms were stained with crystal violet to measure biofilm biomass (n = 3 biological, 3 technical). Error bars indicate mean ± SD. Two-way ANOVA with Tukey’s multiple comparisons test for post-hoc analysis. *p < 0.05, ****p < 0.0001.
Fig. 5Promotion of S. salivarius colonization of Drosophila is MalE and Psl dependent.
A After antibiotic treatment, Drosophila were infected with subcultures of Ss, PAO1, or both species with or without 10 µg/mL α-MalE mAbs. After 24 h, bacterial colony-forming units were enumerated (n = 6 biological replicates, 10 flies per replicate). Two-way ANOVA with Šίdák’s multiple comparisons test. B Quantification of bacterial CFUs per fly after 24-hour colonization with Ss, PAO1, and PAO1ΔpslA. Error bars indicate mean ± SD. One-way ANOVA with Tukey’s multiple comparisons test. *p < 0.05, **p < 0.01.
Fig. 6Environmental and clinical isolates of P. aeruginosa promote dual biofilm formation.
Ss was co-cultured with A environmental, B non-CF acute, or C CF non-mucoid and mucoid isolates of P. aeruginosa in TSBYE with 1% sucrose in a 96-well 16-h biofilm model. Biofilms were stained with crystal violet to measure biofilm biomass (n = 3 biological, 3 technical). Error bars indicate mean ± SD. One-way ANOVA with Dunnett’s multiple comparisons test (A + B). One-way ANOVA with Holm-Šίdák’s multiple comparisons test (C). **p < 0.01, ***p < 0.001, ****p < 0.0001.
Bacterial strains and plasmids.
| Strain | Characteristics | Reference/source |
|---|---|---|
| K12 ( | Wildtype | [ |
| FRD1 ( | CF isolate, mucoid | [ |
| PAO1 ( | Wound isolate, non-mucoid | [ |
| PAO1 | In-frame deletion of | [ |
| PAO1 | Complemented PAO1 | This study |
| PAO1 | Deletion of | [ |
| PA14 ( | Wildtype | [ |
| PAO1-GFP | PAO1 with carbR GFP plasmid | This study |
| Environmental isolates ( | E1-E10 non-mucoid, water isolate | This study |
| AC1 ( | Non-mucoid, urine isolate | Dr. Bill Benjamin UAB Clinical Microbiology Lab |
| AC2 ( | Non-mucoid, wound isolate | Dr. Bill Benjamin UAB Clinical Microbiology Lab |
| AC3 ( | Non-mucoid, urine isolate | Dr. Bill Benjamin UAB Clinical Microbiology Lab |
| AC4 ( | Non-mucoid, bronchial wash isolate | Dr. Bill Benjamin UAB Clinical Microbiology Lab |
| AC5 ( | Non-mucoid, urine isolate | Dr. Bill Benjamin UAB Clinical Microbiology Lab |
| AC6 ( | Non-mucoid, blood isolate | Dr. Bill Benjamin UAB Clinical Microbiology Lab |
| AC7 ( | Non-mucoid, bronchoalveolar lavage isolate | Dr. Bill Benjamin UAB Clinical Microbiology Lab |
| AC8 ( | Non-mucoid, urine isolate | Dr. Bill Benjamin UAB Clinical Microbiology Lab |
| AC9 ( | Non-mucoid | Dr. Bill Benjamin UAB Clinical Microbiology Lab |
| AC10 ( | Non-mucoid, tracheal aspiration isolate | Dr. Bill Benjamin UAB Clinical Microbiology Lab |
| AC11 ( | Non-mucoid, urine isolate | Dr. Bill Benjamin UAB Clinical Microbiology Lab |
| AC12 ( | Non-mucoid, urine isolate | Dr. Bill Benjamin UAB Clinical Microbiology Lab |
| AC13 ( | Non-mucoid, urine isolate | Dr. Bill Benjamin UAB Clinical Microbiology Lab |
| AC14 ( | Non-mucoid, nasal isolate | Dr. Bill Benjamin UAB Clinical Microbiology Lab |
| AC15 ( | Non-mucoid, maxillary sinus isolate | Dr. Bill Benjamin UAB Clinical Microbiology Lab |
| CF clinical isolates ( | CF1-CF3 non-mucoid, CF4-CF6 mucoid | Dr. Susan Birket UAB CF Center |
| DH10b ( | Host strain for cloning | Thermo Fisher |
| pBKSNS1 | pBluescript K(+) ligated to | This study |
Primer sequences.
| Gene | Forward or Reverse | Sequence (5′−3′) | Amplicon size (bp) |
|---|---|---|---|
| Forward | GGATTGGCGGCGTCAGATTT | 2207 | |
| Reverse | TCGATATAGCCGAAGCCGGT | ||
| Forward | CATGCACCTGGCCGAATA | 109 | |
| Reverse | CGGCAGCGAGTTGTAGTT | ||
| 16S rRNA | Forward | GCTGGACTATCGCCGCTG | 150 |
| 16S rRNA | Reverse | ATCTCGTAACCGGTGAAGGTG |